RESEARCH ARTICLE Open Access Cost-effectiveness of abatacept, rituximab, and

treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic more cost-effective than both abatacept and TNFi over a willingness-to-pay range of 0 to 80,000 euros. Conclusions: All three treatment options were similarly effective; however, when costs were factored into th